Tumor Immunology

You have full text access to this OnlineOpen article

Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression

  1. Rita Rotondo1,
  2. Luca Mastracci2,
  3. Tiziana Piazza1,
  4. Gaia Barisione1,
  5. Marina Fabbi1,
  6. Michela Cassanello3,
  7. Roberta Costa4,
  8. Barbara Morandi5,
  9. Simonetta Astigiano1,
  10. Alfredo Cesario6,7,
  11. Maria P. Sormani8,
  12. Guido Ferlazzo5,
  13. Francesco Grossi9,
  14. Giovanni B. Ratto10,
  15. Silvano Ferrini1,†,*,
  16. Guido Frumento1

Article first published online: 4 JUN 2008

DOI: 10.1002/ijc.23437

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1108–1116, 1 September 2008

Additional Information

How to Cite

Rotondo, R., Mastracci, L., Piazza, T., Barisione, G., Fabbi, M., Cassanello, M., Costa, R., Morandi, B., Astigiano, S., Cesario, A., Sormani, M. P., Ferlazzo, G., Grossi, F., Ratto, G. B., Ferrini, S. and Frumento, G. (2008), Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. Int. J. Cancer, 123: 1108–1116. doi: 10.1002/ijc.23437

Author Information

  1. 1

    Department of Translational Oncology, National Institute for Cancer Research, Genoa, Italy

  2. 2

    Department of Surgical, Morphological and Integrated Disciplines, Pathological Anatomy Unit, University of Genoa, Genoa, Italy

  3. 3

    Laboratory for the Study of Inborn Errors of Metabolism, G. Gaslini Institute, Genoa, Italy

  4. 4

    Thoracic Surgery, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy

  5. 5

    Department of Human Pathology, University of Messina, Messina, Italy

  6. 6

    Division of Thoracic Surgery, Catholic University of Rome, Rome, Italy

  7. 7

    Pulmonary Rehabilitation, IRCCS San Raffaele, Rome, Italy

  8. 8

    Department of Health Sciences, Biostatistics Unit, University of Genoa, Genoa, Italy

  9. 9

    Department of Medical Oncology, National Institute for Cancer Research, Genoa, Italy

  10. 10

    Department of Surgical Oncology, National Institute for Cancer Research, Genoa, Italy

  1. †

    Fax: +39 010 5737263.

*Immunopharmacology, National Institute for Cancer Research, c/o IST Nord B2, Largo Rosanna Benzi 10, 16132 Genoa, Italy

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 4 JUN 2008
  3. Manuscript Accepted: 17 DEC 2007
  4. Manuscript Received: 28 MAY 2007

Funded by

  • Fondazione CariVerona, Bando 2004
  • Fondazione Cassa di Risparmio di Torino
  • Fondazione Carige
  • Compagnia di San Paolo
  • Ministero della Salute, Ricerca Finalizzata 2005
  • AIRC
  • FIRC fellowship

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (610K)

References

  • 1
    Rodriguez PC,Zea AH,Culotta KS,Zabaleta J,Ochoa JB,Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 2002; 277: 21123–9.
  • 2
    Jacobsen LC,Theilgaard-Monch K,Christensen EI,Borregaard N. Arginase 1 is expressed in myelocytes/metamyelocytes and localized in gelatinase granules of human neutrophils. Blood 2007; 109: 3084–7.
  • 3
    Munder M,Mollinedo F,Calafat J,Canchado J,Gil-Lamaignere C,Fuentes JM,Luckner C,Doschko G,Soler G,Eichmann K,Muller FM,Ho AD, et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 2005; 105: 2549–56.
  • 4
    Rodriguez PC,Zea AH,DeSalvo J,Culotta KS,Zabaleta J,Quiceno DG,Ochoa JB,Ochoa AC. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003; 171: 1232–9.
  • 5
    Ibiza S,Victor VM,Bosca I,Ortega A,Urzainqui A,O'Connor JE,Sanchez-Madrid F,Esplugues JV,Serrador JM. Endothelial nitric oxide synthase regulates T cell receptor signaling at the immunological synapse. Immunity 2006; 24: 753–65.
  • 6
    Xia Y,Dawson VL,Dawson TM,Snyder SH,Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 1996; 93: 6770–4.
  • 7
    Brito C,Naviliat M,Tiscornia AC,Vuillier F,Gualco G,Dighiero G,Radi R,Cayota AM. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol 1999; 162: 3356–66.
  • 8
    Bronte V,Serafini P,Mazzoni A,Segal DM,Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003; 24: 302–6.
  • 9
    Harris BE,Pretlow TP,Bradley EL,Jr,Whitehurst GB,Pretlow TG. Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma. Cancer Res 1983; 43: 3008–12.
  • 10
    Elgun S,Keskinege A,Yilmaz E,Baltaci S,Beduk Y. Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer. Int Urol Nephrol 1999; 31: 95–9.
  • 11
    Ambs S,Bennett WP,Merriam WG,Ogunfusika MO,Oser SM,Khan MA,Jones RT,Harris C. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer 1998; 78: 233–9.
  • 12
    Liu CY,Wang CH,Chen TC,Lin HC,Yu CT,Kuo H. Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer 1998; 78: 534–41.
  • 13
    Bronte V,Kasic T,Gri G,Gallana K,Borsellino G,Marigo I,Battistini L,Iafrate M,Payer-Galletti T,Pagano F,Viola A. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005; 201: 1257–68.
  • 14
    Chen YM,Yang WK,Whang-Peng J,Tsai WY,Hung YM,Yang DM,Lin WC,Perng RP,Ting CC. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. J Immunother 1997; 20: 354–64.
  • 15
    Pisani RJ,Leibson PJ,McKean DJ. In vitro activation of lymphocytes from nonsmall cell cancer patients by interleukin 2 and anti-CD3 antibody. Clin Immunol Immunopathol 1989; 50: 348–63.
  • 16
    Yano T,Yasumoto K,Togami M,Ishida T,Kimura G,Sugimachi K,Nomoto K. Properties of recombinant interleukin 2-cultured tumor-infiltrating lymphocytes in human lung cancer. Int J Cancer 1989; 43: 619–23.
    Direct Link:
  • 17
    Nakamura H,Ishiguro K,Mori T. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients. Cancer 1988; 62: 2489–97.
    Direct Link:
  • 18
    Semino C,Martini L,Queirolo P,Cangemi G,Costa R,Alloisio A,Ferlazzo G,Sertoli MR,Reali UM,Ratto GB,Melioli G. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience. Anticancer Res 1999; 19: 5645–9.
  • 19
    Melioli G,Ratto G,Guastella M,Meta M,Biassoni R,Semino C,Casartelli G,Pasquetti W,Catrullo A,Moretta L. Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterisation for their use in adoptive immunotherapy. Eur J Cancer 1994; 30A: 97–102.
  • 20
    TravisWD,ColbyTV,CorrinB,ShimosatoY,BrambillaE, eds. Histological typing of lung and pleural tumours. World Health Organization,3rd ed. Berlin: Springer-Verlag, 1999.
  • 21
    WittekindC,GreeneFL,HutterRVP,KlimpfingerM,SobinLH, eds. TNM Atlas,5th ed. Berlin: Springer-Verlag, 2005.
  • 22
    Reiling N,Ulmer AJ,Hauschildt S. Measurement of eNOS and iNOS mRNA expression using reverse transcription polymerase chain reaction. In: TitheradgeMA, ed. Nitric oxide protocols. Totowa: Humana, 1998; 155–161.
  • 23
    Ferreiro CR,Chagas AC,Carvalho MH,Dantas AP,Jatene MB,Bento De Souza LC,Lemos Da Luz P. Influence of hypoxia on nitric oxide synthase activity and gene expression in children with congenital heart disease: a novel pathophysiological adaptive mechanism. Circulation 2001; 103: 2272–6.
  • 24
    Teng B,Murthy KS,Kuemmerle JF,Grider JR,Sase K,Michel T,Makhlouf GM. Expression of endothelial nitric oxide synthase in human and rabbit gastrointestinal smooth muscle cells. Am J Physiol 1998; 275: G342–G351.
  • 25
    Wang ZY,Gaggero A,Rubartelli A,Rosso O,Miotti S,Mezzanzanica D,Canevari S,Ferrini S. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. Int J Cancer 2002; 98: 873–8.
    Direct Link:
  • 26
    Wagner C,Kondella K,Bernschneider T,Heppert V,Wentzensen A,Hansch GM. Post-traumatic osteomyelitis: analysis of inflammatory cells recruited into the site of infection. Shock 2003; 20: 503–10.
  • 27
    Zarco MA,Ribera JM,Urbano-Ispizua A,Filella X,Arriols R,Martinez C,Feliu E,Montserrat E. Phenotypic changes in neutrophil granulocytes of healthy donors after G-CSF administration. Haematologica 1999; 84: 874–8.
  • 28
    Wagner C,Deppisch R,Denefleh B,Hug F,Andrassy K,Hansch GM. Expression patterns of the lipopolysaccharide receptor CD14, and the Fc gamma receptors CD16 and CD64 on polymorphonuclear neutrophils: data from patients with severe bacterial infections and lipopolysaccharide-exposed cells. Shock 2003; 19: 5–12.
  • 29
    Pechkovsky DV,Zissel G,Goldmann T,Einhaus M,Taube C,Magnussen H,Schlaak M,Muller-Quernheim J. Pattern of NOS2 and NOS3 mRNA expression in human A549 cells and primary cultured AEC II. Am J Physiol Lung Cell Mol Physiol 2002; 282: L684–L692.
  • 30
    Williams MS,Noguchi S,Henkart PA,Osawa Y. Nitric oxide synthase plays a signaling role in TCR-triggered apoptotic death. J Immunol 1998; 161: 6526–31.
  • 31
    Eerola AK,Soini Y,Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 2000; 6: 1875–81.
  • 32
    Konishi J,Yamazaki K,Azuma M,Kinoshita I,Dosaka-Akita H,Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10: 5094–100.
  • 33
    Rodriguez PC,Quiceno DG,Ochoa AC. L-Arginine availability regulates T lymphocyte cell cycle progression. Blood 2007; 109: 1568–73.
  • 34
    Mendes Ribeiro AC,Roberts NB,Lane C,Yaqoob M,Ellory JC. Accumulation of the endogenous L-arginine analogue NG-monomethyl-L-arginine in human end-stage renal failure patients on regular haemodialysis. Exp Physiol 1996; 81: 475–81.
  • 35
    Freedland RA,Crozier GL,Hicks BL,Meijer AJ. Arginine uptake by isolated rat liver mitochondria. Biochim Biophys Acta 1984; 802: 407–12.
  • 36
    Soetens O,Crabeel M,El Moualij B,Duyckaerts C,Sluse F. Transport of arginine and ornithine into isolated mitochondria of Saccharomyces cerevisiae. Eur J Biochem 1998; 258: 702–9.
    Direct Link:
  • 37
    Ochoa AC,Zea AH,Hernandez C,Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13: 721s–726s.
  • 38
    Vazquez-Torres A,Jones-Carson J,Mastroeni P,Ischiropoulos H,Fang FC. Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. I. Effects on microbial killing by activated peritoneal macrophages in vitro. J Exp Med 2000; 192: 227–36.
  • 39
    Cheng PN,Lam TL,Lam WM,Tsui SM,Cheng AW,Lo WH,Leung YC. Pegylated recombinant human arginase (rhArg-peg 5,000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007; 67: 309–17.
  • 40
    Shen LJ,Lin WC,Beloussow K,Shen WC. Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 2003; 191: 165–70.
  • 41
    Izzo F,Marra P,Beneduce G,Castello G,Vallone P,De Rosa V,Cremona F,Ensor CM,Holtsberg FW,Bomalaski JS,Clark MA,Ng C, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004; 22: 1815–22.
  • 42
    Ascierto PA,Scala S,Castello G,Daponte A,Simeone E,Ottaiano A,Beneduce G,De Rosa V,Izzo F,Melucci MT,Ensor CM,Prestayko AW, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005; 23: 7660–8.
View Full Article (HTML) Get PDF (610K)